Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
193 The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies
Compose a Response to This Article
Other responses
No responses have been published for this article.